Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients
BACKGROUND: The angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension (HT). Whether the use of these drugs increases the infectivity of novel coronavirus and results in an additional risk for morbidity and mortal...
Guardado en:
Autores principales: | Seyma Baslilar, Bengu Saylan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
King Faisal Specialist Hospital and Research Centre
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/151dc1962fe54498bb6e4427e08addf7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang C, et al.
Publicado: (2021) -
Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials.
por: Jia Yao, et al.
Publicado: (2021) -
Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Jin-Ying Fang, et al.
Publicado: (2020) -
Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia
por: Selçuk Görmez, et al.
Publicado: (2021) -
Comparative efficacy and predictive value of fixed combination of amlodipine and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in patients with coronary heart disease, post-infarction cardiosclerosis and hypertension
por: M. M. Dolzhenko, et al.
Publicado: (2021)